Badlands Ranch Launches New Superfood Complete Bison & Beef Formula
LOS ANGELES, March 21, 2025 /PRNewswire/ -- Badlands Ranch®, the premium pet nutrition brand founded by actress and animal advocate Katherine Heigl, is excited to announce the launch of its newest recipe, Superfood Complete Bison & Beef. This carefully crafted, air-dried dog food is designed to provide dogs with high-quality nutrition that supports smooth digestion, strong muscles, and overall vitality.*
What is Badlands Ranch Superfood Complete Bison & Beef?Badlands Ranch Superfood Complete Bison & Beef Formula is a premium, air-dried dog food made with some of the most wholesome and beneficial ingredients on Earth. This nutrient-rich recipe is packed with protein-dense bison and beef, nutrient-loaded organ meats, heart-healthy salmon, and gut-supporting vegetables and fruits—all selected to help support a dog's digestion, energy levels, and overall wellness. At Badlands Ranch, sourcing matters. That's why the brand partners with suppliers who prioritize animal welfare. Each ingredient is carefully air-dried at low temperatures to preserve its natural nutrients—ensuring that every meal is packed with the goodness dogs need to thrive.*
What is Inside Badlands Ranch Superfood Complete Bison & Beef?
87% Premium Proteins: Bison, beef, beef heart, beef liver, beef tripe, and salmon provide high-quality protein to support muscle strength and overall health.*
13% Fruits, Vegetables & Seeds: Fiber-rich sweet potatoes and pumpkin help support gut health, while antioxidant-packed chia seeds and blueberries offer essential nutrients.*
What it does NOT contain: Corn, Soy, Wheat, or Fillers: Every bite is crafted with clean, responsibly sourced ingredients, free from unnecessary additives.
Badlands Ranch Superfood Complete Bison & Beef Formula FAQ
Where can I purchase Badlands Ranch Superfood Complete Bison & Beef?
Badlands Ranch Superfood Complete Bison & Beef can be purchased at www.badlandsranch.com for the price of $69.95 per bag. Badlands Ranch provides free shipping on U.S. orders over $50 and a 90-day money-back guarantee (minus shipping).
How do I incorporate Badlands Ranch Superfood Complete Bison & Beef into my dog's diet?
To help your dog's digestive system adjust to Badlands Ranch Superfood Complete, gradually transition by slowly increasing the amount of Superfood Complete while decreasing their previous food. Continue this process until their bowl is entirely filled with Superfood Complete. For the smoothest transition, refer to the chart on the Badlands Ranch website. Additionally, serve fresh, clean water with each meal, and for dogs who have trouble chewing, mix the food with water for easier digestion.
Are there other flavors of Badlands Ranch Superfood Complete?
Yes, Badlands Ranch Superfood complete comes in several flavors including: Beef, Chicken, Lamb & Venison, and Wild Fish & Turkey.
About Badlands RanchFounded by Katherine Heigl, in collaboration with animal nutritionists, Badlands Ranch is an ultra-premium pet nutrition brand that provides carefully crafted pet food, treats, and supplements for optimal canine health. Badlands Ranch products are created using the highest quality, safety standards, and cooking practices to ensure maximum freshness and nutritional content. Each ingredient is hand-selected to support your dog's skin and coat, digestion, immune system, energy, and a well-balanced overall diet. Badlands Ranch currently offers dog food, treats, and supplements. To learn more about Badlands Ranch visit www.badlandsranch.com, @BadlandsRanchPets on Instagram and Facebook, Youtube, @BadlandsPets on Tiktok, and @BadlandsPets on Twitter.
About Katherine HeiglFounder of Badlands Ranch, Katherine Heigl, is an Emmy Award-winning and two-time Golden Globe-nominated actress and producer. She is best known for her starring roles in the feature films "The Ugly Truth," "27 Dresses" and "Knocked Up," as well as her work on ABC's critically acclaimed drama "Grey's Anatomy." In the latest news, Heigl starred in and executive produced the second season of the Netflix series "Firefly Lane," an adaptation of the best-selling novel by author Kristin Hannah. Heigl is married to singer-songwriter Josh Kelley, and they live together in Utah, where they have three children and eight dogs. For the latest Katherine Heigl news, follow @katherineheigl on Instagram.
*All pets are unique. Results can and will vary.
Media ContactDana Lewisdana@danalewispr.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/badlands-ranch-launches-new-superfood-complete-bison--beef-formula-302407678.html
SOURCE Badlands Ranch
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
16 hours ago
- Business Wire
Theraclion Growth Up in S1 2025
MALAKOFF, France--(BUSINESS WIRE)--Regulatory News: THERACLION (ISIN: FR0010120402; Mnemo: ALTHE), an innovative company developing Sonovein®, a robotic platform for non-invasive High-Intensity Focused Ultrasound (HIFU) varicose vein treatment, reviews its business for S1 2025. Sales of consumables (recurring revenue) up 30% compared to 2024 New treatment centers opened in Bulgaria and Spain Appointment of a new business manager and acceleration of commercial activities On-schedule completion of the follow-up period for the pivotal FDA clinical trial Martin Deterre, CEO of Theraclion, states: "In early 2025, Theraclion stepped up Sonovein's activity. In June, the final 12-month follow-ups for patients in the pivotal FDA-approved clinical trial were completed on-schedule. We are now awaiting the final results, which we expect to publish in September. Theraclion has also entered a business development phase: building a sales and marketing team, opening two new Sonovein treatment centers, and achieving significant growth in recurring revenue — all of which promise the achievement of our ambitious goals." Commercial activity acceleration As part of its business development, Theraclion is actively building its sales and marketing team. In May 2025, Thibault Le Normand joined the company as Chief Business Officer to boost sales in the Middle East and product placements (PPUs) of Sonovein in Europe. With over a decade of experience in international development of medical devices, Thibault Le Normand brings valuable expertise to this strategic growth phase. At the same time, the technological credibility and clinical maturity of Sonovein have been further demonstrated by the publication of new scientific articles as well as by over a dozen presentations at major international congresses by renowned physicians using the device. Sonovein's international profile has also increased through Theraclion's participation in congresses, such as Vein in Venice (April, Venice), Venous Symposium (May, New York), and the European Venous Forum (June, Krakow). This outreach effort was supported by the launch of a new product identity and a new website, giving Sonovein a new brand image that reflects innovation, clinical excellence, and ambition. In addition, two new product placement (PPU) contracts for Sonovein have been signed in Bulgaria and Spain, stepping up Theraclion's presence in Europe and expanding the installed base of the technology. Revenue for S1 2025 Theraclion's revenue for S1 2025 was €835K, up 89% compared to 2024 (€442K) (prior to the non-recurring adjustment of €680K related to the cancellation of Echopulse system sales in 2024). Consumables, which include recurring revenues from PPUs, was up 30% compared to S1 2024. Service revenues were up 232% over the same period. This strong momentum is a key indicator of increasing use of Sonovein by treatment centers and reflects the technology's sustained traction in the field. Combined, consumables and services — representing recurring revenue — was up 57% compared to 2024. Progress of the pivotal FDA clinical trial In the USA, the pivotal FDA-approved study for SONOVEIN® reached a major milestone in June 2025 with the on-schedule completion of the 12-month post-treatment patient follow-ups. Data analysis is currently underway, with results expected in September. Submission of the marketing authorization application to the FDA is planned for Fall 2025, with potential approval estimated for Q2 2026, subject to the FDA's processing time. This progress marks a critical strategic milestone in the work to access the world's largest market for venous disease treatment. Next financial publication: Theraclion will publish its interim financial results on October 29, 2025. About Theraclion Theraclion is a French MedTech company committed to developing a non-invasive alternative to surgery through the innovative use of focused ultrasound. High Intensity Focused Ultrasound (HIFU) does not require incisions or an operating room, leaves no scars, and patients can immediately resume their routines. HIFU treatment concentrates therapeutic ultrasounds on an internal focal point from outside the body. Theraclion is developing SONOVEIN®, a CE-marked, a robotic platform for HIFU varicose vein treatment, which could replace millions of surgical procedures every year. In the USA, SONOVEIN® is an investigational device limited to investigational use; it is not available for sale in the USA. Based in Malakoff (Paris), the Theraclion team comprises some 30 people, most of them involved in technological and clinical development. Theraclion is listed on Euronext Growth Paris Eligible for the PEA-PME scheme Mnemonic: ALTHE - ISIN code: FR0010120402 LEI: 9695007X7HA7A1GCYD29
Yahoo
17 hours ago
- Yahoo
Proteomics Market to Expand Rapidly, with 13% CAGR forecast Through 2030
"Advances in proteomics technologies are driving growth in precision medicine, with rising demand for early diagnostics, personalized therapies, and deeper insights into disease mechanisms." BOSTON, July 25, 2025 /PRNewswire/ -- According to the latest study from BCC Research, "Proteomics: Technologies and Global Markets" was valued at $27.6 billion in 2024 and is projected to grow from $31.0 billion in 2025 to $57.2 billion by the end of 2030, at a compound annual growth rate (CAGR) of 13.0% from 2025 to 2030. The report offers a detailed analysis of the global market for proteomic technologies, segmented by product type (instruments and software, consumables), platform (mass spectrometry, biochip), application (drug discovery and development, research, diagnostics, applied proteomics), and region (North America, Europe, Asia-Pacific, and Rest of the World). Protein structural analysis and protein-expression products are outside the scope of the report. The study discusses market trends, challenges, and emerging technologies, while also examining the competitive landscape and the market shares of leading vendors. It includes a section on ESG trends and provides company profiles that include insights into financials, product portfolios, and recent advances. This analysis serves as a valuable resource for understanding strategic opportunities and market dynamics in the evolving proteomics sector. This report is particularly relevant today due to the growing demand for innovative and personalized therapies, which is driving advances in proteomic technologies. Increased investments in R&D are accelerating the discovery of new biomarkers, which are crucial for early and accurate diagnosis of diseases. These trends underscore the importance of proteomics in shaping the future of precision medicine and improving healthcare outcomes. The factors driving the market's growth include: Increasing Investments in R&D: Governments, biotech firms, and academic institutions are increasing funding in proteomics research to drive innovation in diagnostics, drug discovery, and therapeutic development. Transition Towards Personalized Medicine: Proteomics enables the identification of protein biomarkers that support tailored treatments based on individual biological profiles, making it a cornerstone in the shift toward personalized healthcare. Aging Population and Prevalence of Chronic Diseases: As the global population ages, chronic conditions like cancer and cardiovascular diseases are becoming more common, increasing the demand for proteomics tools that aid in early detection and targeted treatment. Emerging Technologies: Advances such as high-resolution mass spectrometry, AI-driven data analysis, and single-cell proteomics are accelerating research making it more precise, and cost-effective, thereby expanding the scope and impact of proteomics. Request a sample copy of the global market for proteomic technologies report. Report Synopsis Report Metric Details Base year considered 2024 Forecast period considered 2025-2030 Base year market size $27.6 billion Market size forecast $57.2 billion Growth rate CAGR of 13.0% from 2025 to 2030 Segments covered Platform, Application, Product Type and Region Regions covered North America, Europe, Asia-Pacific and the Rest of the World (RoW) Countries covered U.S., Canada, Mexico, Germany, the U.K., Italy, France, Spain, Japan, China, India, South Korea, Rest of Asia-Pacific, and Rest of Europe Market drivers Increasing investments in R&D. Transition towards personalized medicine. Aging population and growing prevalence of chronic diseases. Emerging technologies. Interesting facts: Advances in Technology: The market has seen notable progress in mass spectrometry, particularly with improvements in software and automation that streamline essential processes like sample preparation. Innovation from Emerging Companies: Start-up companies such as Nautilus and SomaLogic have introduced innovative platforms that are expected to reshape the market's future. Emerging startup: Alamar Biosciences Nautilus Biotechnology Pixelgen Technologies Syncell Inc. Sengenics The report addresses the following questions: What is the projected size and growth rate of the market?- The global proteomics market was valued at $27.6 billion in 2024 and is expected to grow at a CAGR of 13% to reach $57.2 billion by the end of 2030. Which factors are driving the growth of the market?- The global market of proteomic technologies is growing due to the rising aging population and growing prevalence of chronic diseases, increasing investments in R&D and in the biotechnology sector, and rising demand for personalized medicine. Which market segments are covered in the report?- The global market for proteomic technologies is segmented based on platform, product type, application, and region. Which platform type will be dominant through 2030?- The mass spectrometry segment will be dominant through 2030. Which region has the largest market share?- North America holds the largest share of the market. Market Leaders include: AGILENT TECHNOLOGIES INC. ARRAYIT CORP. BIO-RAD LABORATORIES INC. BIO-TECHNE BRUKER CREATIVE PROTEOMICS DANAHER CORP. JEOL LTD. MERCK KGAA PROMEGA CORP. REVVITY SHIMADZU CORP. STANDARD BIOTOOLS THERMO FISHER SCIENTIFIC INC. WATERS CORP. Related reports: Single-Cell Genomics and Proteomics: Emerging Technologies and Markets: This report reviews the single-cell genomics and proteomics market, highlighting its current landscape and future potential. It examines key market drivers, challenges, and opportunities, and segments the market by product type (genomics, epigenomics, transcriptomics), application areas (oncology and immunology), end users (academic institutions and biotech companies), and regions (North America, Europe, Asia-Pacific, and the Rest of the World). It also includes profiles of major companies, covering their business segments, financials, product offerings, and recent developments. Global Multiomics Market: This report provides a detailed analysis of the global multiomics market, focusing on products, platforms, applications, end-users, and regions. It explores market trends and forecasts, along with insights into major players and geographic opportunities. The report also includes strategic tools like PESTEL and ESG analysis, competitive assessments, and recommendations to help companies plan effectively. Purchase a copy of the report direct from BCC Research. For further information on any of these reports or to make a purchase, contact info@ About BCC Research BCC Research market research reports provide objective, unbiased measurement and assessment of market opportunities. Our experienced industry analysts' goal is to help you make informed business decisions free of noise and hype. Contact Us Corporate HQ: 50 Milk St., Ste. 16, Boston, MA 02109, USAEmail: info@ +1 781-489-7301 For media inquiries, email press@ or visit our media page for access to our market research library. Any data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. Logo - View original content to download multimedia: SOURCE BCC Research LLC
Business Wire
20 hours ago
- Business Wire
Bradford Health Services Earns Coveted "Great Place To Work"® Certification
BIRMINGHAM, Ala.--(BUSINESS WIRE)-- Bradford Health Services, a leading provider of drug and alcohol addiction treatment across the Southeastern U.S., today announced it has been officially certified as a Great Place To Work®. This recognition, awarded by the global authority on workplace culture, underscores Bradford Health's commitment to building a supportive, inclusive, and high-trust environment for its more than 1,600 U.S.-based employees. 'This certification is a reflection of the servant-leadership philosophy that guides us at Bradford,' said Rob Marsh, Chief Executive Officer. Share Bradford Health achieved certification with 67% of employees reporting a positive experience at work, surpassing the typical U.S.-based company average of 57%. Key areas of strength highlighted by employees include: 89% agree they are entrusted with significant responsibilities. 86% say their work has special meaning beyond being 'just a job,' and that they felt welcomed upon joining. 84% affirm they feel they make a difference in the organization. 82% report they can be themselves at work. 'This certification is a reflection of the servant-leadership philosophy that guides us at Bradford,' said Rob Marsh, Chief Executive Officer. 'We've built a culture where our people come first—where leaders exist to support, uplift, and empower our teams to live out our mission with purpose and compassion.' Great Place To Work® conducts its evaluations using its proprietary Trust Index™ survey and Trust Model™, which assess culture across five pillars: credibility, respect, fairness, pride, and camaraderie. About Bradford Health Services With 40 years of experience, Bradford Health Services operates addiction treatment centers in Alabama, Florida, Mississippi, North Carolina, Tennessee, and Texas. The organization is accredited by The Joint Commission and delivers evidence-based care at every stage of the recovery journey. About Great Place To Work® Certification Great Place To Work® Certification ™ is the gold standard for workplace culture recognition. Based on anonymous employee feedback, the certification recognizes organizations that foster high levels of trust, pride, and camaraderie.
